The Boulder-based firm, which recently completed a 12-week Phase 2 trial for the drug, plans to share further insights during an investor webcast today. Chief Scientific Officer Alan Russell noted that the molecule was selected from over 7,000 candidates specifically for its ability to provide positive lusitropic properties—enhancing the heart's relaxation phase—while avoiding the systolic liabilities often associated with earlier treatments.
In section Releases
Edgewise Therapeutics details mechanism for heart drug EDG-7500
Edgewise Therapeutics is unveiling new data on EDG-7500, a first-in-class cardiac sarcomere modulator designed to treat hypertrophic cardiomyopathy by targeting the regulatory light chain. The company reports that the drug improves cardiac relaxation in preclinical models without compromising the heart's systolic function or its ability to pump blood effectively.
Early clinical observations in patients with symptomatic hypertrophic cardiomyopathy appear to mirror these preclinical findings, suggesting a potential path forward for both obstructive and nonobstructive forms of the disease. With the current data supporting its safety profile, Edgewise Therapeutics is preparing to launch a Phase 3 trial by the end of 2026. The company intends to publish a peer-reviewed article detailing the drug's mechanism of action later today, providing a deeper look at how this approach aims to restore cardiac equilibrium in patients facing limited functional capacity due to left ventricular stiffness.
Comments (0)
No comments yet. Be the first!